

Statement of Advice:

ceritinib 150mg hard capsules (Zykadia®)
Novartis Pharmaceuticals UK Ltd

SMC No 1333/18

9 March 2018

ADVICE: in the absence of a submission from the holder of the marketing authorisation

ceritinib (Zykadia®) is not recommended for use within NHS Scotland.

Indication under review: As monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Chairman
Scottish Medicines Consortium